Total Payments
$572,843
2024 Payments
$3,309
Companies
31
Transactions
574
Medicare Patients
730
Medicare Billing
$294,556
Payment Breakdown by Category
Consulting$296,939 (51.8%)
Other$199,454 (34.8%)
Travel$39,589 (6.9%)
Research$22,826 (4.0%)
Food & Beverage$13,495 (2.4%)
Education$460.94 (0.1%)
Gifts$78.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $296,939 | 72 | 51.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,554 | 69 | 31.9% |
| Travel and Lodging | $39,589 | 123 | 6.9% |
| Unspecified | $22,826 | 27 | 4.0% |
| Honoraria | $16,900 | 6 | 3.0% |
| Food and Beverage | $13,495 | 253 | 2.4% |
| Education | $460.94 | 23 | 0.1% |
| Gift | $78.75 | 1 | 0.0% |
Payments by Type
General
$550,017
547 transactions
Research
$22,826
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $234,712 | 229 | $0 (2022) |
| EMD Serono, Inc. | $75,816 | 72 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $39,025 | 59 | $0 (2024) |
| Genentech USA, Inc. | $33,883 | 35 | $0 (2023) |
| GENZYME CORPORATION | $29,835 | 14 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $27,902 | 49 | $0 (2018) |
| Celgene Corporation | $19,712 | 11 | $0 (2019) |
| Horizon Therapeutics plc | $18,323 | 19 | $0 (2023) |
| F. Hoffmann-La Roche AG | $14,384 | 17 | $0 (2023) |
| Greenwich Biosciences, Inc. | $11,642 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,309 | 6 | EMD Serono, Inc. ($2,179) |
| 2023 | $29,235 | 25 | Horizon Therapeutics plc ($11,126) |
| 2022 | $37,164 | 54 | Biogen, Inc. ($15,142) |
| 2021 | $41,557 | 28 | Biogen, Inc. ($15,888) |
| 2020 | $72,542 | 51 | Biogen, Inc. ($44,278) |
| 2019 | $118,723 | 146 | Biogen, Inc. ($46,537) |
| 2018 | $144,048 | 140 | Biogen, Inc. ($66,628) |
| 2017 | $126,266 | 124 | Biogen, Inc. ($46,240) |
All Payment Transactions
574 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/10/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/01/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/29/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | — | Cash or cash equivalent | $1,080.75 | Research |
| Study: COMB157GUS12 • Category: Neurology | ||||||
| 02/16/2024 | EMD Serono, Inc. | — | Gift | In-kind items and services | $78.75 | General |
| 01/25/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 01/17/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/14/2023 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $412.42 | General |
| 12/12/2023 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 11/21/2023 | Mylan Specialty L.P. | — | Consulting Fee | Cash or cash equivalent | $5,530.50 | General |
| 09/09/2023 | Mylan Specialty L.P. | — | Travel and Lodging | In-kind items and services | $34.30 | General |
| 08/16/2023 | Merck KGaA | Evobrutinib | Consulting Fee | Cash or cash equivalent | $2,385.00 | General |
| 08/16/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Immunology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,006.08 | Research |
| Study: Employment and Patient-Reported Outcomes in Ocrelizumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: 2-Year CASTING and CHORDS Data • Category: Immunology | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Honoraria | Cash or cash equivalent | $7,150.00 | General |
| Category: UPLIZNA | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $171.02 | General |
| Category: UPLIZNA | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: UPLIZNA | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: UPLIZNA | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: UPLIZNA | ||||||
| 06/16/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: UPLIZNA | ||||||
| 06/15/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | In-kind items and services | $416.48 | General |
| Category: UPLIZNA | ||||||
| 06/15/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Travel and Lodging | In-kind items and services | $313.25 | General |
| Category: UPLIZNA | ||||||
| 06/15/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: UPLIZNA | ||||||
| 05/09/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Honoraria | Cash or cash equivalent | $2,750.00 | General |
| Category: UPLIZNA | ||||||
| 04/24/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| 04/11/2023 | EMD Serono, Inc. | Evobrutinib | Consulting Fee | Cash or cash equivalent | $5,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,747 | 7 |
| AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $4,078 | 6 |
| Publication support research related | Novartis Pharma AG | $4,015 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $1,825 | 1 |
| EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS A 6 MONTH OPEN LABEL MULTI CENTER PHASE III B STUDY EXPANDED | Novartis Pharmaceuticals Corporation | $1,727 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,562 | 4 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,200 | 2 |
| COMB157GUS12 | Novartis Pharmaceuticals Corporation | $1,081 | 1 |
| Employment and Patient-Reported Outcomes in Ocrelizumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: 2-Year CASTING and CHORDS Data | F. Hoffmann-La Roche AG | $1,006 | 1 |
| AN OPEN LABEL STUDY TO ASSESS RESPONSE TO INFLUENZA VACCINE IN OFATUMUMAB TREATED PATIENTS. | Novartis Pharmaceuticals Corporation | $570.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 212 | 3,413 | $194,710 | $133,272 |
| 2022 | 9 | 221 | 3,354 | $188,249 | $123,245 |
| 2021 | 4 | 164 | 317 | $40,943 | $22,818 |
| 2020 | 3 | 133 | 210 | $30,656 | $15,221 |
Total Patients
730
Total Services
7,294
Medicare Billing
$294,556
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 12 | 2,860 | $140,140 | $107,592 | 76.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 140 | $34,020 | $16,522 | 48.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 60 | $5,880 | $2,805 | 47.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 21 | 25 | $5,475 | $2,257 | 41.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 69 | $3,243 | $1,326 | 40.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 16 | $2,416 | $1,176 | 48.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 59 | $1,888 | $920.94 | 48.8% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 22 | 160 | $1,600 | $653.90 | 40.9% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 17 | 24 | $48.00 | $17.80 | 37.1% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 11 | 2,820 | $138,180 | $99,383 | 71.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 89 | 128 | $29,312 | $13,855 | 47.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 22 | 74 | $7,252 | $3,840 | 53.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 29 | $4,379 | $2,001 | 45.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 15 | $3,285 | $1,369 | 41.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 12 | 47 | $2,209 | $1,058 | 47.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 14 | 61 | $1,952 | $999.41 | 51.2% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 21 | 165 | $1,650 | $726.65 | 44.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 14 | 15 | $30.00 | $13.78 | 45.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 101 | 159 | $30,870 | $17,461 | 56.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 41 | $5,911 | $3,080 | 52.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 17 | 34 | $3,332 | $1,914 | 57.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2021 | 12 | 83 | $830.00 | $363.34 | 43.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 102 | 170 | $24,480 | $12,239 | 50.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 20 | 24 | $4,608 | $2,215 | 48.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 11 | 16 | $1,568 | $767.31 | 48.9% |
About Dr. Bianca Weinstock Guttman, MD
Dr. Bianca Weinstock Guttman, MD is a Neurology healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710957501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bianca Weinstock Guttman, MD has received a total of $572,843 in payments from pharmaceutical and medical device companies, with $3,309 received in 2024. These payments were reported across 574 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($296,939).
As a Medicare-enrolled provider, Weinstock Guttman has provided services to 730 Medicare beneficiaries, totaling 7,294 services with total Medicare billing of $294,556. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Buffalo, NY
- Active Since 01/24/2006
- Last Updated 04/11/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1710957501
Products in Payments
- TECFIDERA (Drug) $61,099
- TYSABRI (Biological) $52,585
- OCREVUS (Biological) $39,439
- VUMERITY (Drug) $28,634
- AUBAGIO (Drug) $24,069
- UPLIZNA (Drug) $18,323
- Ozanimod (Drug) $16,456
- Mavenclad (Biological) $16,091
- COPAXONE (Drug) $14,896
- Rebif (Biological) $12,776
- Non-Covered Product (Drug) $12,763
- GILENYA (Drug) $12,109
- MAYZENT (Drug) $11,837
- Copaxone (Drug) $8,688
- Evobrutinib $7,685
- PLEGRIDY (Biological) $7,346
- Epidiolex (Drug) $6,373
- FTY720D (Drug) $4,243
- ARZERRA (Drug) $3,942
- Ocrevus (Biological) $3,933
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Buffalo
David Hojnacki, Md, MD
Neurology — Payments: $633,608
Neurology $633,608
Nicholas Silvestri, M.d, M.D
Neurology — Payments: $628,943
Neurology $628,943
Dr. Gil Wolfe, Md, MD
Neurology — Payments: $624,527
Neurology $624,527
Dr. Channa Kolb, M.d, M.D
Neurology — Payments: $202,591
Neurology $202,591
Dr. Robert Glover, M.d, M.D
Neurology — Payments: $65,561
Neurology $65,561
Svetlana Eckert, M.d, M.D
Neurology — Payments: $51,514
Neurology $51,514